Converting patients from warfarin to non-vitamin K antagonist oral anticoagulants

被引:0
作者
Romanelli, Sarah [1 ,2 ]
Rivera, Veronica [1 ]
机构
[1] Mt Sinai Hosp, Martha Stewart Ctr Living, Brookdale Dept Geriatr & Palliat Med, New York, NY USA
[2] Mt Sinai Hosp, Martha Stewart Ctr Living, Brookdale Dept Geriatr & Palliat Med, 1468 Madison Ave,Annenberg Bldg 10th Floor Box 107, New York, NY 10029 USA
关键词
Anticoagulant; atrial fibrillation; geriatrics; primary health care; quality improvement; warfarin; ATRIAL-FIBRILLATION;
D O I
10.1097/JXX.0000000000000857
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background:Non-vitamin K antagonist oral anticoagulants (NOACs) are favorable in stroke prevention for geriatric patients with nonvalvular atrial fibrillation versus warfarin. These anticoagulants do not require international normalized ratio (INR) monitoring and have lower food/drug interactions. In addition, NOACs have risk reduction in bleeding and all-cause mortality compared with warfarin.Local problem:At a geriatric primary care practice, two registered nurses manage 88 patients on warfarin for INR monitoring. Nurse practitioners (NPs) provide oversight for warfarin titration after abnormal results. The goal of this quality-improvement project was to decrease the time spent monitoring patients on warfarin.Methods:Primary care providers and cardiologists of patients on warfarin were contacted to gain approval of transition to a NOAC. The NP reviewed patients' renal function and the indication for anticoagulation and then created a list of eligible patients for transition.Interventions:Patients eligible for transition to NOACs were contacted for their consent. The transition process included stopping warfarin, ordering apixaban, ordering INR level, educating about starting apixaban, and coordinating appropriate follow-up.Results:Of 88 patients on warfarin, 21 were eligible for conversion from warfarin to apixaban. Of these 21 patients, 66% (n = 14) consented to the conversion. Of those who were not converted to apixaban, five declined due to cost and two were lost to follow-up.Conclusion:There was a reduction in nurses' monthly monitoring of patients on warfarin by 22%. Transition to NOAC was not only beneficial for patient safety and efficacy but also reduced nursing clinical time for anticoagulation encounters.
引用
收藏
页码:380 / 385
页数:6
相关论文
共 12 条
  • [1] Bristol Myers Squibb, 2021, EL AP FULL PRESCR IN
  • [2] Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex
    Carnicelli, Anthony P.
    Hong, Hwanhee
    Connolly, Stuart J.
    Eikelboom, John
    Giugliano, Robert P.
    Morrow, David A.
    Patel, Manesh R.
    Wallentin, Lars
    Alexander, John H.
    Cecilia Bahit, M.
    Benz, Alexander P.
    Bohula, Erin A.
    Chao, Tze-Fan
    Dyal, Leanne
    Ezekowitz, Michael
    A.a. Fox, Keith
    Gencer, Baris
    Halperin, Jonathan L.
    Hijazi, Ziad
    Hohnloser, Stefan H.
    Hua, Kaiyuan
    Hylek, Elaine
    Toda Kato, Eri
    Kuder, Julia
    Lopes, Renato D.
    Mahaffey, Kenneth W.
    Oldgren, Jonas
    Piccini, Jonathan P.
    Ruff, Christian T.
    Steffel, Jan
    Wojdyla, Daniel
    Granger, Christopher B.
    [J]. CIRCULATION, 2022, 145 (04) : 242 - 255
  • [3] January CT, 2019, CIRCULATION, V140, pE125, DOI [10.1161/CIR.0000000000000665, 10.1016/j.jacc.2019.01.011]
  • [4] Keown A., 2020, COURT WIN BMS PFIZER
  • [5] Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients The ARISTOPHANES Study
    Lip, Gregory Y. H.
    Keshishian, Allison
    Li, Xiaoyan
    Hamilton, Melissa
    Masseria, Cristina
    Gupta, Kiran
    Luo, Xuemei
    Mardekian, Jack
    Friend, Keith
    Nadkarni, Anagha
    Pan, Xianying
    Baser, Onur
    Deitelzweig, Steven
    [J]. STROKE, 2018, 49 (12) : 2933 - 2944
  • [6] Antithrombotic Therapy for Atrial Fibrillation CHEST Guideline and Expert Panel Report
    Lip, Gregory Y. H.
    Banerjee, Amitava
    Boriani, Giuseppe
    Chiang, Chern en
    Fargo, Ramiz
    Freedman, Ben
    Lane, Deirdre A.
    Ruff, Christian T.
    Turakhia, Mintu
    Werring, David
    Patel, Sheena
    Moores, Lisa
    [J]. CHEST, 2018, 154 (05) : 1121 - 1201
  • [7] Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
    Lopez-Lopez, Jose A.
    Sterne, Jonathan A. C.
    Thom, Howard H. Z.
    Higgins, Julian P. T.
    Hingorani, Aroon D.
    Okoli, George N.
    Davies, Philippa A.
    Bodalia, Pritesh N.
    Bryden, Peter A.
    Welton, Nicky J.
    Hollingworth, William
    Caldwell, Deborah M.
    Savovic, Jelena
    Dias, Sofia
    Salisbury, Chris
    Eaton, Diane
    Stephens-Boal, Annya
    Sofat, Reecha
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2017, 359
  • [8] Pricing Information, 2022, AFIB PRIC INF RX ELI
  • [9] Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation A Systematic Review and Meta-Analysis
    Proietti, Marco
    Romanazzi, Imma
    Romiti, Giulio Francesco
    Farcomeni, Alessio
    Lip, Gregory Y. H.
    [J]. STROKE, 2018, 49 (01) : 98 - +
  • [10] Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients
    Schaefer, Andreas
    Flierl, Ulrike
    Berliner, Dominik
    Bauersachs, Johann
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2020, 34 (04) : 555 - 568